|
|
NNRTIs in Development
- An Alternative NNRTI, TMC278, Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Drugs From Old Classes (Spring 2006)
A listing of NNRTIs, NRTIs and protease inhibitors currently in development.
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
- NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body
- BILR 355 BS, a Second-Generation NNRTI, Shows Activity Against Most Common NNRTI Mutations (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- GW695634 Demonstrates Potent Activity in 7-Day Monotherapy Study in an NNRTI Treatment-Experienced Population (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- An Overview of Capravirine (July 11, 2005)
To read PDF, click here
From U.S. National Institutes of Health
- Pfizer Discontinues Development of Capravirine, for HIV/AIDS (July 1, 2005)
From Pfizer, Inc.
- Early Pre-Clinical Development of GW8248 Promising (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- New Anti-HIV Therapies: Capravirine (January 2003)
From Project Inform
- New Anti-HIV Therapies: Other New NNRTIs (January 2003)
From Project Inform
- Pharmacokinetics of MKC-422, One of the Next Non-Nucleoside Reverse Transcriptase Inhibitors, Together With ZDV, 3TC, d4T, and ddI (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
|
|
